MGRC Healthcare, De Cell in tie-up to advance Exogenetix
Malaysian Genomics Resource Centre Bhd (MGRC) unit MGRC Healthcare Sdn Bhd has teamed up with De Cell Bhd to advance the Exogenetix programme, aiming to set new standards in cell-gene therapy development and commercialisation.
MGRC Healthcare will use its expertise in biopharmaceuticals to provide technical and production support, as well as improving the operational efficiency and market deployment of Exogenetix.
De Cell Bhd will handle marketing responsibilities of the programme.
MGRC Healthcare said the collaboration underscored its commitment to innovation in healthcare and its dedication to pushing the boundaries of medical science.
“By combining production capabilities with marketing expertise (of both companies), the partnership aims to significantly expand the impact of the Exogenetix programme.”
MGRC Healthcare executive chairman Azri Azerai said the partnership not only aligned with its strategic vision to deliver cutting-edge healthcare solutions but also reinforced its dedication to pushing the boundaries of medical science.
“Through this partnership, we are set to accelerate the development and delivery of next-generation cell-gene therapies, ultimately improving patient outcomes. “We are eager to see the transformative impact this collaboration will have on the healthcare industry,” said De Cell director Dr Lim Wooi Khai.
“This strategic alliance aims to support the evolution of the biopharmaceutical sector by integrating advanced biotechnologies with effective marketing strategies, thereby addressing the increasing needs for sophisticated therapeutic options.”